Latest Cardiovascular Systems (CSII) Headlines
Post# of 31
Posted On: 03/13/2014 7:13:58 AM
Latest Cardiovascular Systems (CSII) Headlines
Cardiovascular Systems Announces First Peripheral Arterial Disease Case Treated with New, Low-Profile, 60cm Diamondback Peripheral System
Business Wire - Wed Mar 12, 10:00AM CDT
Cardiovascular Systems, Inc. (NASDAQ: CSII) (CSI), today announced the first use of its Diamondback 360(R) 60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD). Jihad A. Mustapha, M.D., FACC, FSCAI, Director of Heart and Vascular at Metro Health Hospital in Wyoming, Mich., performed the procedure through Tibiopedal access using the new, low-profile device.
Cardiovascular Systems Receives FDA Clearance for Low Profile, 60cm Diamondback Devices Designed to Expand the Treatment of Peripheral Artery Disease (PAD)
Business Wire - Mon Mar 10, 7:01AM CDT
Cardiovascular Systems, Inc. (NASDAQ: CSII) (CSI), announced today it has received FDA clearance of its new Diamondback 360(R) 60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD).
Cardiovascular Systems Releases One-Year Orbit II Coronary Data at 2014 Cardiovascular Research Technologies Conference
Business Wire - Tue Feb 25, 6:01AM CST
--Cost savings in excess of $4,000 per patient treated versus current standard of care
Cardiovascular Systems to Present ORBIT II Coronary Data at 2014 Cardiovascular Research Technologies Conference
Business Wire - Thu Feb 20, 10:15AM CST
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), will release one-year data from the ORBIT II study of the company's Diamondback 360(R) Coronary Orbital Atherectomy System in treating severely calcified lesions. The data will be presented as an iMPACT Trial at the 2014 Cardiovascular Research Technologies (CRT) conference in Washington, D.C., Feb. 22-25, 2014. CRT's iMPACT Trials are innovative reports that provide the latest breakthroughs in clinical science. The studies selected for the iMPACT Trials session at CRT are expected to highlight new improvements for quality of patient care, and significantly impact the field of interventional cardiology.
T-Mobile Austria Selects NetScout to Assure National LTE Network
Business Wire - Wed Feb 19, 7:30AM CST
NetScout(R) Systems, Inc. today announced that T-Mobile Austria has selected NetScout to assure service delivery and provide operational intelligence for their national Long Term Evolution (LTE) network, expanding NetScout's existing deployment in T-Mobile's third-generation (3G) HSPA+ network. The nGenius(R) solution provides T-Mobile with a single service assurance platform to support data and multimedia services to assure a seamless subscriber experience on and between their 2G, 3G and LTE networks.
Use Options For A Chance To Buy CSII At A 32% Discount
at The Street - Mon Feb 03, 11:06AM CST
Looking back to 75 days ago, Cardiovascular Systems priced a 2,608,696 share secondary stock offering at $30 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the...
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 30, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Cardiovascular Systems, Inc. Shares Are Feeling Pumped
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 30, 1:30PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cardiovascular Systems , a medical device...
Upgrade Alert for Cardiovascular Systems (CSII)
Comtex SmarTrend(R) - Thu Jan 30, 8:00AM CST
Cardiovascular Systems (NASDAQ:CSII) was upgraded from Hold to Buy at Benchmark Co. today. The stock closed yesterday at $29.41 on volume of 377,000 shares, above average daily volume of 294,000. In the past 52 weeks, Cardiovascular Systems share prices have been bracketed by a low of $13.28 and a high of $34.72 and closed yesterday at $29.41, 121% above that low price. The 200-day and 50-day moving averages have moved 0.67% higher and 0.12% lower over the past week, respectively.
Cardiovascular Systems Reports Fiscal 2014 Second-Quarter Financial Results
Business Wire - Wed Jan 29, 3:00PM CST
--Revenues rose 28 percent for both the second quarter and first half of fiscal 2014
Covidien Beats on Q1 Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 1:41PM CST
Covidien posted first-quarter fiscal 2014 adjusted earnings per share from continuing operations of $1.00, up 3.09% year over year.
FDA OKs Covidien's Novel Jaw Device - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 6:00PM CST
Covidien's LigaSure Maryland jaw gets the FDA approval.
Medtronic's SureScan Wins FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 3:43PM CST
Medtronic gets FDA approval to use its SureScan pacing systems for full body MRI scans without positioning restrictions
Baxter Beats on Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 3:07PM CST
For full year 2013, Baxter's net earnings inched up 2.0% to $2,567 million from $2,516 million a year ago
Physician Demand Continues to Build for Cardiovascular Systems' New Coronary Artery Disease Treatment Technology
Business Wire - Thu Jan 23, 8:00AM CST
--Deborah Heart and Lung Center, Brown Mills, N.J.
Covidien to Exit Renal Denervation Market - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 22, 5:40PM CST
Covidien announces to pull out OneShot system
St. Jude Beats on 4Q Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 22, 10:10AM CST
For full-year 2013, St. Jude's adjusted net earnings rose 8.0% to $3.76 per share from $3.48 per share in the prior year
Covidien Completes Confluent Surgical Sale - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 3:00PM CST
The Confluent Surgical product line comprises soft tissue repair division of COV's Medical Devices segment
Cardiovascular Systems to Webcast Fiscal 2014 Second-Quarter Earnings Conference Call Wednesday, January 29
Business Wire - Tue Jan 21, 12:00PM CST
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2014 second-quarter conference call on Wednesday, Jan. 29, 2014, at 3:45 p.m. CT (4:45 p.m. ET). David Martin, president and chief executive officer, and Larry Betterley, chief financial officer, will discuss the company's results for its fiscal second quarter ended December 31, 2013, and its financial outlook. The company will issue a post-market earnings release prior to the call on Jan. 29.
Cardiovascular Systems Announces First Peripheral Arterial Disease Case Treated with New, Low-Profile, 60cm Diamondback Peripheral System
Business Wire - Wed Mar 12, 10:00AM CDT
Cardiovascular Systems, Inc. (NASDAQ: CSII) (CSI), today announced the first use of its Diamondback 360(R) 60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD). Jihad A. Mustapha, M.D., FACC, FSCAI, Director of Heart and Vascular at Metro Health Hospital in Wyoming, Mich., performed the procedure through Tibiopedal access using the new, low-profile device.
Cardiovascular Systems Receives FDA Clearance for Low Profile, 60cm Diamondback Devices Designed to Expand the Treatment of Peripheral Artery Disease (PAD)
Business Wire - Mon Mar 10, 7:01AM CDT
Cardiovascular Systems, Inc. (NASDAQ: CSII) (CSI), announced today it has received FDA clearance of its new Diamondback 360(R) 60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD).
Cardiovascular Systems Releases One-Year Orbit II Coronary Data at 2014 Cardiovascular Research Technologies Conference
Business Wire - Tue Feb 25, 6:01AM CST
--Cost savings in excess of $4,000 per patient treated versus current standard of care
Cardiovascular Systems to Present ORBIT II Coronary Data at 2014 Cardiovascular Research Technologies Conference
Business Wire - Thu Feb 20, 10:15AM CST
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), will release one-year data from the ORBIT II study of the company's Diamondback 360(R) Coronary Orbital Atherectomy System in treating severely calcified lesions. The data will be presented as an iMPACT Trial at the 2014 Cardiovascular Research Technologies (CRT) conference in Washington, D.C., Feb. 22-25, 2014. CRT's iMPACT Trials are innovative reports that provide the latest breakthroughs in clinical science. The studies selected for the iMPACT Trials session at CRT are expected to highlight new improvements for quality of patient care, and significantly impact the field of interventional cardiology.
T-Mobile Austria Selects NetScout to Assure National LTE Network
Business Wire - Wed Feb 19, 7:30AM CST
NetScout(R) Systems, Inc. today announced that T-Mobile Austria has selected NetScout to assure service delivery and provide operational intelligence for their national Long Term Evolution (LTE) network, expanding NetScout's existing deployment in T-Mobile's third-generation (3G) HSPA+ network. The nGenius(R) solution provides T-Mobile with a single service assurance platform to support data and multimedia services to assure a seamless subscriber experience on and between their 2G, 3G and LTE networks.
Use Options For A Chance To Buy CSII At A 32% Discount
at The Street - Mon Feb 03, 11:06AM CST
Looking back to 75 days ago, Cardiovascular Systems priced a 2,608,696 share secondary stock offering at $30 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the...
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 30, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Cardiovascular Systems, Inc. Shares Are Feeling Pumped
Sean Williams, The Motley Fool - Motley Fool - Thu Jan 30, 1:30PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cardiovascular Systems , a medical device...
Upgrade Alert for Cardiovascular Systems (CSII)
Comtex SmarTrend(R) - Thu Jan 30, 8:00AM CST
Cardiovascular Systems (NASDAQ:CSII) was upgraded from Hold to Buy at Benchmark Co. today. The stock closed yesterday at $29.41 on volume of 377,000 shares, above average daily volume of 294,000. In the past 52 weeks, Cardiovascular Systems share prices have been bracketed by a low of $13.28 and a high of $34.72 and closed yesterday at $29.41, 121% above that low price. The 200-day and 50-day moving averages have moved 0.67% higher and 0.12% lower over the past week, respectively.
Cardiovascular Systems Reports Fiscal 2014 Second-Quarter Financial Results
Business Wire - Wed Jan 29, 3:00PM CST
--Revenues rose 28 percent for both the second quarter and first half of fiscal 2014
Covidien Beats on Q1 Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 1:41PM CST
Covidien posted first-quarter fiscal 2014 adjusted earnings per share from continuing operations of $1.00, up 3.09% year over year.
FDA OKs Covidien's Novel Jaw Device - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 6:00PM CST
Covidien's LigaSure Maryland jaw gets the FDA approval.
Medtronic's SureScan Wins FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 3:43PM CST
Medtronic gets FDA approval to use its SureScan pacing systems for full body MRI scans without positioning restrictions
Baxter Beats on Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 3:07PM CST
For full year 2013, Baxter's net earnings inched up 2.0% to $2,567 million from $2,516 million a year ago
Physician Demand Continues to Build for Cardiovascular Systems' New Coronary Artery Disease Treatment Technology
Business Wire - Thu Jan 23, 8:00AM CST
--Deborah Heart and Lung Center, Brown Mills, N.J.
Covidien to Exit Renal Denervation Market - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 22, 5:40PM CST
Covidien announces to pull out OneShot system
St. Jude Beats on 4Q Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 22, 10:10AM CST
For full-year 2013, St. Jude's adjusted net earnings rose 8.0% to $3.76 per share from $3.48 per share in the prior year
Covidien Completes Confluent Surgical Sale - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 3:00PM CST
The Confluent Surgical product line comprises soft tissue repair division of COV's Medical Devices segment
Cardiovascular Systems to Webcast Fiscal 2014 Second-Quarter Earnings Conference Call Wednesday, January 29
Business Wire - Tue Jan 21, 12:00PM CST
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2014 second-quarter conference call on Wednesday, Jan. 29, 2014, at 3:45 p.m. CT (4:45 p.m. ET). David Martin, president and chief executive officer, and Larry Betterley, chief financial officer, will discuss the company's results for its fiscal second quarter ended December 31, 2013, and its financial outlook. The company will issue a post-market earnings release prior to the call on Jan. 29.
(0)
(0)Cardiovascular Systems Inc. (CSII) Stock Research Links
Scroll down for more posts ▼